at www.tipranks.com (Thu, 30-Jul 10:50 AM)
Damora Therapeutics: Buy Rating Reaffirmed on Differentiated ET/MF Candidate and $50 Price Target
at www.tipranks.com (Sun, 26-Jul 4:05 PM)
Damora Therapeutics Sets Sights on Clinical Milestones for Groundbreaking mutCALR Therapies in 2026
Market Chameleon (Wed, 13-May 8:46 AM)
